A systematic review and meta‐analysis of neoadjuvant imatinib use in locally advanced and metastatic gastrointestinal stromal tumors

Abstract

AbstractBackgroundSeveral doubts remain regarding the optimal use of neoadjuvant imatinib in gastrointestinal stromal tumors (GISTs), such as ideal treatment duration, patient selection, and long‐term survival outcomes. This manuscript provides a comprehensive review on neoadjuvant imatinib treatment outcomes and facilitate evidence‐based decision‐making for the use of imatinib therapy in GISTs.MethodsFour databases (PubMed, EMBASE, Scopus, and Cochrane Library) were searched from inception to September 9, 2023. Meta‐analyses of proportions were performed for the outcomes of R0 resection, disease responses, and 1‐year, 3‐year, and 5‐year overall survival (OS) as well as 1‐year, 3‐year, and 5‐year disease free survival (DFS). Sensitivity analyses in the form of leave‐one‐out analyses, meta‐regression, and subgroup analyses were performed for outcomes with substantial statistical heterogeneity.ResultsThe search yielded 1254 articles, and 36 studies were included in our analysis. Meta‐analysis of proportions revealed that 1‐year, 3‐year, and 5‐year OS was 100%, 94%, and 88%, while 1‐year, 3‐year and 5‐year DFS was 99%, 89%, and 79%, respectively. An R0 resection rate of 89% and a disease response rate of 67% was achieved after a mean duration of treatment of 8.41 ± 0.367 months. KIT exon 9 mutation was significantly associated with poorer 5‐year DFS.ConclusionThis study quantified key outcomes for neoadjuvant imatinib in locally advanced and metastatic or recurrent GIST. Patients with gastric and rectal tumous stand to benefit from neoadjuvant imatinib with an optimal treatment duration of 8 months. Furthermore, the potential utility of mutational analysis in guiding treatment with neoadjuvant imatinib was demonstrated.